杰尼斯:一种针对ERβ的新型雌激素模拟剂,以缓解血小板缺血症
Xiaoqin Tang1,2, Rui Liao1,2, Ling Zhou1,2
1Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou,646000, China.
International journal of biological sciences
|April 15, 2024
概括
雌激素模拟物Genistin通过促进血小板的产生来治疗血小板缺血. 这种化合物增强了巨核细胞的分化,并在辐射诱导的血小板缺血模型中显示出潜在的作用.
科学领域:
- 血液学 血液学 血液学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血小板缺血是各种疾病死亡的重要危险因素.
- 对于血小板缺血的现有治疗方法有局限性.
- 雌激素在血栓形成中的作用尚不清楚.
研究的目的:
- 为了确定新型的治疗药物用于血小板缺血.
- 为了研究基尼斯的潜力,一种雌激素模拟物,在治疗血小板缺血.
- 阐明基尼斯对血小板生产的作用机制.
主要方法:
- 由人工智能驱动的复合图书馆选以识别基因组.
- 在体外研究评估基尼斯对巨核细胞分化的影响.
- 在体内研究评估基尼斯在辐射诱导的血小板缩模型中的疗效.
- 涉及雌激素受体β (ERβ) 和信号通路 (ERK1/2,Akt) 的机制研究.
主要成果:
- 基尼斯被确定为对血小板缺血的潜在治疗剂.
- 热尼斯显著增强了巨核细胞的分化,导致血小板的产生增加.
- 基尼斯在辐射诱导的血小板缺血的小鼠模型中显示出治疗潜力.
- 基尼斯与膜ERβ直接相互作用,激活ERK1/2和Akt通路.
结论:
- 热尼斯代表了对血小板缺血的有希望的治疗候选者.
- 热尼斯的机制涉及ERβ激活和下游信号通路.
- 这项研究强调了雌激素信号传递和血小板产生之间的新联系.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522


